CHEK
Price
$1.82
Change
-$0.27 (-12.92%)
Updated
Oct 17 closing price
Capitalization
10.65M
37 days until earnings call
Intraday Buy/Sell Signals
WRBY
Price
$21.70
Change
+$0.17 (+0.79%)
Updated
Oct 17 closing price
Capitalization
2.65B
19 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CHEK vs WRBY

Header iconCHEK vs WRBY Comparison
Open Charts CHEK vs WRBYBanner chart's image
Check-Cap
Price$1.82
Change-$0.27 (-12.92%)
Volume$204.32K
Capitalization10.65M
Warby Parker
Price$21.70
Change+$0.17 (+0.79%)
Volume$1.92M
Capitalization2.65B
CHEK vs WRBY Comparison Chart in %
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WRBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHEK vs. WRBY commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHEK is a Hold and WRBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (CHEK: $1.82 vs. WRBY: $21.70)
Brand notoriety: CHEK and WRBY are both not notable
CHEK represents the Medical Specialties, while WRBY is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CHEK: 5% vs. WRBY: 122%
Market capitalization -- CHEK: $10.65M vs. WRBY: $2.65B
CHEK [@Medical Specialties] is valued at $10.65M. WRBY’s [@Pharmaceuticals: Other] market capitalization is $2.65B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $159.93B to $0. The average market capitalization across the [@Medical Specialties] industry is $11.57B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHEK’s FA Score shows that 1 FA rating(s) are green whileWRBY’s FA Score has 0 green FA rating(s).

  • CHEK’s FA Score: 1 green, 4 red.
  • WRBY’s FA Score: 0 green, 5 red.
According to our system of comparison, CHEK is a better buy in the long-term than WRBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHEK’s TA Score shows that 7 TA indicator(s) are bullish while WRBY’s TA Score has 5 bullish TA indicator(s).

  • CHEK’s TA Score: 7 bullish, 4 bearish.
  • WRBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CHEK is a better buy in the short-term than WRBY.

Price Growth

CHEK (@Medical Specialties) experienced а -1.09% price change this week, while WRBY (@Pharmaceuticals: Other) price change was -2.52% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.25%. For the same industry, the average monthly price growth was +3.05%, and the average quarterly price growth was +51.76%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.29%. For the same industry, the average monthly price growth was +0.51%, and the average quarterly price growth was +14.72%.

Reported Earning Dates

CHEK is expected to report earnings on Nov 24, 2025.

WRBY is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Medical Specialties (+0.25% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (-0.29% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WRBY($2.65B) has a higher market cap than CHEK($10.6M). CHEK YTD gains are higher at: 83.857 vs. WRBY (-10.368). WRBY has higher annual earnings (EBITDA): 30.7M vs. CHEK (-17.34M). WRBY has more cash in the bank: 286M vs. CHEK (1.08M). CHEK has less debt than WRBY: CHEK (0) vs WRBY (228M). WRBY has higher revenues than CHEK: WRBY (821M) vs CHEK (0).
CHEKWRBYCHEK / WRBY
Capitalization10.6M2.65B0%
EBITDA-17.34M30.7M-56%
Gain YTD83.857-10.368-809%
P/E RatioN/AN/A-
Revenue0821M-
Total Cash1.08M286M0%
Total Debt0228M-
FUNDAMENTALS RATINGS
CHEK: Fundamental Ratings
CHEK
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
14

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHEKWRBY
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WRBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGRCX24.52N/A
N/A
Loomis Sayles Growth C
GITAX33.21N/A
N/A
Goldman Sachs Technology Opps A
NDVVX17.63N/A
N/A
MFS New Discovery Value R6
PGIRX26.96N/A
N/A
Polen Global Growth Investor
TBLTX12.79N/A
N/A
Transamerica Balanced II I3

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and IINN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and IINN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
-12.92%
IINN - CHEK
29%
Poorly correlated
-1.79%
TWST - CHEK
26%
Poorly correlated
-8.42%
WRBY - CHEK
25%
Poorly correlated
+0.79%
SENS - CHEK
25%
Poorly correlated
-3.61%
MYGN - CHEK
23%
Poorly correlated
-3.47%
More

WRBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, WRBY has been loosely correlated with TWST. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if WRBY jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WRBY
1D Price
Change %
WRBY100%
+0.79%
TWST - WRBY
45%
Loosely correlated
-8.42%
ISRG - WRBY
44%
Loosely correlated
+2.65%
GKOS - WRBY
43%
Loosely correlated
+2.16%
RGEN - WRBY
42%
Loosely correlated
-1.26%
MMSI - WRBY
42%
Loosely correlated
+1.30%
More